Altered levels of insulin-like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction

2010 ◽  
Vol 30 (9) ◽  
pp. 815-820 ◽  
Author(s):  
Julian K. Christians ◽  
Andrée Gruslin
Keyword(s):  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Binding Protein ◽  
Growth Restriction ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Intrauterine Growth

scholarly journals Increased Insulin-like Growth Factor Binding Protein-1 Phosphorylation in Decidualized Stromal Mesenchymal Cells in Human Intrauterine Growth Restriction Placentas

2018 ◽  
Vol 66 (9) ◽  
pp. 617-630 ◽  
Author(s):  
Sahil S. Singal ◽  
Karen Nygard ◽  
Robert Gratton ◽  
Thomas Jansson ◽  
Madhulika B. Gupta
Keyword(s):  
Growth Factor ◽  
Gestational Age ◽  
Intrauterine Growth Restriction ◽  
Binding Protein ◽  
Growth Restriction ◽  
Insulin Like Growth Factor ◽  
Maternal Circulation ◽  
Endometrial Stromal Cells ◽  
Factor Binding ◽  
Intrauterine Growth

Intrauterine growth restriction (IUGR) is often caused by placental insufficiency, which is believed to be associated with decreased delivery of oxygen and nutrients to the placental barrier. We recently reported that hypoxia and/or leucine deprivation triggered hyperphosphorylation of insulin-like growth factor binding protein-1 (IGFBP-1) in decidualized human immortalized endometrial stromal cells (HIESCs), resulting in decreased insulin-like growth factor-1 (IGF-1) bioactivity. To test the hypothesis that human IUGR is associated with increased decidual IGFBP-1 phosphorylation at discrete sites, we used IUGR and gestational age matched appropriate for gestational age (AGA) placentas ( n=5 each). We performed dual immunofluorescence immunohistochemistry (IHC) using IGFBP-1 and vimentin as decidual and mesenchymal markers, respectively. Employing a unique strategy with imaging software, we extracted signal intensity of IGFBP-1 expressed specifically from truly decidualized cells of the placenta. Relative IGFBP-1 was increased (85%; p=0.0001) and using custom phospho-site-specific antibodies, we found that IGFBP-1 phosphorylation (pSer101; +40%, p=0.0677/pSer119; +60%, p=0.0064/pSer169; +100%, p=0.0021) was markedly enhanced in IUGR. Together, our data links for the first time, increased decidual IGFBP-1 phosphorylation at discrete sites with human IUGR. These novel findings suggest that hyperphosphorylation of IGFBP-1 in decidualized stromal mesenchymal decidua basalis contributes to potentially elevated levels of phosphorylated IGFBP-1 in maternal circulation in IUGR pregnancies.

Differential regulation of igf1 and igf1r mRNA levels in the two hepatic lobes following intrauterine growth restriction and its treatment with intra-amniotic insulin-like growth factor-1 in ovine fetuses

2010 ◽  
Vol 22 (8) ◽  
pp. 1188 ◽  
Author(s):  
Revati A. Darp ◽  
Hendrina A. de Boo ◽  
Hui Hui Phua ◽  
Mark H. Oliver ◽  
José G. B. Derraik ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Venous Blood ◽  
Growth Restriction ◽  
Mrna Levels ◽  
Insulin Like Growth Factor ◽  
Hepatic Lobe ◽  
Intrauterine Growth ◽  
The Right ◽  
Gut Maturation

Intrauterine growth restriction (IUGR) has life-long health implications, yet there is no effective prenatal treatment. Daily intra-amniotic administration of insulin-like growth factor (IGF)-1 to IUGR fetal sheep improves fetal gut maturation but suppresses hepatic igf1 gene expression. Fetal hepatic blood supply is regulated, in part, by shunting of oxygen- and nutrient-rich umbilical venous blood through the ductus venosus, with the left hepatic lobe predominantly supplied by umbilical venous blood and the right hepatic lobe predominantly supplied by the portal circulation. We hypothesised that: (1) once-weekly intra-amniotic IGF-1 treatment of IUGR would be effective in promoting gut maturation; and (2) IUGR and its treatment with intra-amniotic IGF-1 would differentially affect igf1 and igf1r mRNA expression in the two hepatic lobes. IUGR fetuses received 360 µg IGF-1 or saline intra-amniotically once weekly from 110 until 131 days gestation. Treatment of IUGR fetuses with IGF-1 reversed impaired gut growth. In unembolised, untreated control fetuses, igf1 mRNA levels were 19% lower in the right hepatic lobe than in the left; in IUGR fetuses, igf1 and igf1r mRNA levels were sixfold higher in the right lobe. IGF-1 treatment reduced igf1 and igf1r mRNA levels in both lobes compared with IUGR fetuses. Thus, weekly intra-amniotic IGF-1 treatment, a clinically feasible approach, reverses the impaired gut development seen in IUGR. Furthermore, igf1 and igf1r mRNA levels are differentially expressed in the two hepatic lobes and relative expression in the two lobes is altered by both IUGR and intra-amniotic IGF-1 treatment.

Association of Insulin-like Growth Factor-II Apa1 and MspI Polymorphisms with Intrauterine Growth Restriction Risk

2020 ◽  
pp. 1-7 ◽  
Author(s):  
Mojgan Karimi-Zarchi ◽  
Leila Zanbagh ◽  
Atiyeh Javaheri ◽  
Razieh Sadat Tabatabaei ◽  
Hajar Abbasi ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Growth Restriction ◽  
Insulin Like Growth Factor ◽  
Intrauterine Growth ◽  
Factor Ii
Sign in / Sign up

Export Citation Format

Share Document